|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
|
|
2
|
Saltz LB and Minsky B: Adjuvant therapy of
cancers of the colon and rectum. Surg Clin North Am. 82:1035–1058.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krook JE, Moertel CG, Gunderson LL, et al:
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
N Engl J Med. 324:709–715. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seiwert TY, Salama JK and Vokes EE: The
concurrent chemoradiation paradigm - general principles. Nat Clin
Pract Oncol. 4:86–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iyer R, Fetterly G, Lugade A and Thanavala
Y: Sorafenib: a clinical and pharmacologic review. Expert Opin
Pharmacother. 11:1943–1955. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siegel AB, Olsen SK, Magun A and Brown RS
Jr: Sorafenib: where do we go from here? Hepatology. 52:360–369.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Escudier BET, Stadler WM, Szczylik C,
Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan
M, Simantov R and Bukowski RM; TARGET Study Group. Sorafenib in
advanced clear-cell renal-cell carcinoma. New Engl J Med.
356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gupta-Abramson V, Troxel AB, Nellore A, et
al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin
Oncol. 26:4714–4719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takimoto CH and Awada A: Safety and
anti-tumor activity of sorafenib (Nexavar) in combination with
other anti-cancer agents: a review of clinical trials. Cancer
Chemother Pharmacol. 61:535–548. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kumar P, Benedict R, Urzua F, Fischbach C,
Mooney D and Polverini P: Combination treatment significantly
enhances the efficacy of antitumor therapy by preferentially
targeting angiogenesis. Lab Invest. 85:756–767. 2005. View Article : Google Scholar
|
|
13
|
Plastaras JP, Kim SH, Liu YY, et al: Cell
cycle-dependent and schedule-dependent antitumor effects of
sorafenib combined with radiation. Cancer Res. 67:9443–9454. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dal Lago L, D’Hondt V and Awada A:
Selected combination therapy with sorafenib: a review of clinical
data and perspectives in advanced solid tumors. Oncologist.
13:845–858. 2008.PubMed/NCBI
|
|
15
|
Azad N, Annunziata C, Barrett T, et al:
Dual targeting of vascular endothelial growth factor (VEGF) with
sorafenib and bevacizumab: clinical and translational results. J
Clin Oncol (Meeting abstracts). 25:35422007.
|
|
16
|
Kasibhatla M, Steinberg P, Meyer J,
Ernstoff MS and George DJ: Radiation therapy and sorafenib:
clinical data and rationale for the combination in metastatic renal
cell carcinoma. Clin Genitourin Cancer. 5:291–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Horgan AM, Dawson LA, Swaminath A and Knox
JJ: Sorafenib and radiation therapy for the treatment of advanced
hepatocellular carcinoma. J Gastrointest Cancer. 43:344–348. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jeong YK, Kim MS, Lee JY, et al: Sorafenib
acts synergistically in combination with radiotherapy without
causing intestinal damage in colorectal cancer. Tumori. 99:176–182.
2013.PubMed/NCBI
|
|
19
|
Jackson SP: Sensing and repairing DNA
double-strand breaks. Carcinogenesis. 23:687–696. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bonner WM, Redon CE, Dickey JS, et al:
GammaH2AX and cancer. Nat Rev Cancer. 8:957–967. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bourton EC, Plowman PN, Smith D, Arlett CF
and Parris CN: Prolonged expression of the γ-H2AX DNA repair
biomarker correlates with excess acute and chronic toxicity from
radiotherapy treatment. Int J Cancer. 129:2928–2934. 2011.
|
|
23
|
Collis SJ, DeWeese TL, Jeggo PA and Parker
AR: The life and death of DNA-PK. Oncogene. 24:949–961. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smith GC and Jackson SP: The DNA-dependent
protein kinase. Genes Dev. 13:916–934. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Douglas P, Sapkota G, Morrice N, et al:
Identification of in vitro and in vivo phosphorylation sites in the
catalytic subunit of the DNA-dependent protein kinase. Biochem J.
368:243–251. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pignochino Y, Grignani G, Cavalloni G, et
al: Sorafenib blocks tumour growth, angiogenesis and metastatic
potential in preclinical models of osteosarcoma through a mechanism
potentially involving the inhibition of ERK1/2, MCL-1 and ezrin
pathways. Mol Cancer. 8:1182009. View Article : Google Scholar
|
|
27
|
Basset P, Okada A, Chenard MP, et al:
Matrix metalloproteinases as stromal effectors of human carcinoma
progression: therapeutic implications. Matrix Biol. 15:535–541.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johnsen M, Lund LR, Rømer J, Almholt K and
Danø K: Cancer invasion and tissue remodeling: common themes in
proteolytic matrix degradation. Curr Opin Cell Biol. 10:667–671.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
